Nexium Esomeprazole Sodium for Injection

1. Indications and Usage
Gastroesophageal Reflux Disease: As an alternative to oral therapy when oral therapy is not feasible.
Acute Peptic Ulcer Bleeding: For the treatment of low-risk patients with acute gastric or duodenal ulcer bleeding (endoscopic Forrest grades IIc-III) when oral therapy is not feasible.
2. Dosage and Administration
Recommended Dose: For gastroesophageal reflux disease, 20 mg or 40 mg once daily. For acute peptic ulcer bleeding, 40 mg every 12 hours for 5 days.
Duration: Usually administered for a short period (not exceeding 7 days). Oral therapy should be initiated as soon as possible.
Administration: Must be administered intravenously. The injection time should be at least 3 minutes, or intravenous infusion over 30 minutes.
3. Mechanism of Action
Target: Esomeprazole sodium is the sodium salt of esomeprazole, the S-isomer of omeprazole.
Action: It is a specific inhibitor of gastric H+/K+-ATPase, selectively blocking the final step of gastric acid production in parietal cells.
4. Safety and Warnings
Bone Fracture: Long-term use of proton pump inhibitors (PPIs) may increase the risk of osteoporosis-related fractures of the hip, wrist, or spine.
Hypomagnesemia: Severe hypomagnesemia has been reported with prolonged PPI use (usually after 3 months).
CDAD: Use may alter intestinal flora and increase the risk of Clostridium difficile-associated diarrhea.
Renal and Acute Interstitial Nephritis: Acute interstitial nephritis has been observed with PPIs.
Cutaneous and Systemic Lupus Erythematosus: New onset or worsening of existing lupus has been reported.
5. Adverse Reactions and Clinical Research
Adverse Reactions: Common adverse reactions include headache, diarrhea, nausea, vomiting, abdominal pain, constipation, and flatulence.
Clinical Research: Clinical trials have demonstrated high efficacy in healing erosive esophagitis and controlling acute upper gastrointestinal bleeding compared to standard care.
6. Drug Interactions
Clopidogrel: Esomeprazole may decrease the effect of clopidogrel by inhibiting its conversion to the active metabolite.
CYP2C19 Substrates: Esomeprazole may increase plasma concentrations of drugs metabolized by CYP2C19, such as diazepam, phenytoin, and citalopram.
Drugs Affected by Gastric pH: Absorption of drugs requiring acidic gastric pH (e.g., ketoconazole, itraconazole, iron salts) may be reduced.
Nelfinavir: Concomitant use with nelfinavir is contraindicated.
7. Pharmaceutical Information
Composition: The active ingredient is esomeprazole sodium. Excipients typically include disodium edetate and sodium hydroxide.
Appearance: White or off-white lyophilized block or powder.
Storage: Store protected from moisture and light. Reconstituted solutions should be used within 12 hours.